^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Mesothelioma |
| Drug: | IK-930 (TEAD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2156 - IK-930 is a novel TEAD inhibitor for the treatment of cancers harboring mutations in the Hippo signal transduction pathway
Published date:
03/09/2022
Excerpt:
Daily oral administration of IK-930 resulted in antitumor activity in Hippo-dysregulated mesothelioma xenograft models. In EGFR or KRAS mutated tumors, IK-930 enhanced apoptosis and in vivo antitumor activity in combination with EGFR and MEK inhibitors, respectively.
Secondary therapy:
MEK Inhibitor + THE-349
